ArticleInternational journal of molecular sciences2026
Glutathione Delivery Using a Furcellaran-Chitosan System: Effects of Microencapsulation and Incorporation Strategy on Digestion in a Food Matrix.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The aim of this study was to evaluate the impact of glutathione (GSH), applied in free form and in the form of microcapsules, on the release and nutritional properties of a functional post-exercise recovery snack. Five snack variants enriched with free GSH or microencapsulated GSH, applied using different incorporation strategies, were prepared and subjected to standardised in vitro digestion following the INFOGEST protocol. The study assessed GSH levels in the digesta, protein and fat digestibility, antioxidant capacity, and changes in fatty acid profiles after digestion. Snacks fortified with free GSH exhibited the highest immediate GSH levels in the digesta (up to 2390 ± 240 nmol/mL), whereas lower levels were observed for microencapsulated GSH (down to 1280 ± 132 nmol/mL), reflecting differences in release behaviour under in vitro digestion conditions. Products containing microencapsulated GSH showed a markedly higher post-digestion free amino acid content (1520 ± 100 mg/100 g) compared with those enriched with free GSH (820.3 ± 19 mg/100 g), indicating differences in the profile of protein digestion products. Antioxidant activity and phenolic content increased after digestion across all formulations, with no consistent differences between variants, while fat digestibility remained unchanged, although fatty acid profiles differed depending on the GSH application form. Overall, the results indicate that the form of GSH incorporation, including microencapsulation, influences its behaviour during in vitro digestion and affects the release and distribution of compounds within the food matrix.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.